National Cancer Center

Koken Company, Limited

Takeda Chemical Industries, Inc.

Daiichi Pharmaceutical Co., Ltd.

Dainippon Sumitomo Pharma Co., Ltd.

Sumitomo Pharmaceuticals Company Limited

Masaaki Terada

Takahiro Ochiya

Koichi Igarashi

Koji Yoshimura

Akihiko Sano

Makoto Tsukamoto

Kaori Ishimaru

Shunji Nagahara

Takashi Sugimura

Sho Yoshida

Teruo Miyata

Hiroshi Itoh

Yoshio Kozai

Teruhiko Yoshida

Yu Aso

Hiromi Sakamoto

Kimi Honma

Akihiko Hisada

Shunji 3-348 Sumitomokagaku Nagahara

Masayasu Furuse

Shunichiro Kubota

Takahiro 218 National Cancer Center Ochiya

Means for transferring efficiently a desired nucleic acid into a cell is provided. The present invention comprises using a complex comprising a collagen or a collagen derivative, and a desired nucleic acid.

Method of promoting nucleic acid transfer

The invention is directed to the retention of the stability of formulations useful for a gene therapy during the preparation and preservation. In the invention, at least one saccharide and/or at least one non-hydrophobic amino acid and/or at least one organic acid having two or more carboxyl groups except amino acids, or a collagen or a gelatin and at least one amino acid are added to a gene formulation.

Stable gene preparations

The present invention relates to gene preparations comprising desired genes or vectors containing desired genes integrated there into and carriers for supporting the same. The carrier is preferably a soluble collagen such as atelocollagen and may further include an additive. The invention also encompasses methods for delivering genes to cells employing the gene preparation.

Gene preparations

The present invention provides a gene-containing composition including a gene and a transporter, the transporter being capable of transporting the gene from a pregnant body to fetal cells. When this composition is administered to a pregnant body, birth of offsprings with gene deficiency can be prevented, and gene deficiency can be treated during pregnancy. In animal experiments, when an unknown gene is introduced to animals during their embryogenic stage, the function of the gene in ontogenesis can be elucidated. Moreover, the composition can be used for breeding animals such as pets, industrial animals and cattle.

Gene-containing compositions

The present invention provides a polypeptide represented by the following amino acid sequence:

Nucleic acids encoding HST 2 muteins

The present invention provides a polypeptide represented by the following amino acid sequence: ##STR1## wherein n is 0 or 1 and X represents Pro Ala Gly Thr Arg Ala Asn Asn Thr Leu Leu Asp Ser Arg Gly Trp Gly Thr Leu Leu Ser Arg Ser Arg Ala Gly or a fragment thereof (n=0: SEQ ID NO:1, n=1: SEQ ID NO:2), a recombinant DNA coding for the polypeptide, a vector containing the recombinant DNA, the preparation of a transformant carrying the vector, and the production of the polypeptide with the transformant. The use of this peptide in pharmaceutical compositions is also provided.

Hst-2 muteins, pharmaceutical compositions and kits comprising same, and

A deletion type mutein of heparin-binding secretory transforming factor (hst-1) possesses excellent cell growth promoting activity and is stable. The present mutein can therefore be used as a therapeutic medicine such as a healing promoter for burns, wounds, surgical injuries etc.

Deletion muteins of hst-1

Growing community of inventors

Tokyo, Japan

Masaaki Terada